These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
451 related articles for article (PubMed ID: 10717256)
1. Hepatitis C virus: kinetics and quasispecies evolution during anti-viral therapy. Zeuzem S Forum (Genova); 2000; 10(1):32-42. PubMed ID: 10717256 [TBL] [Abstract][Full Text] [Related]
3. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C. Pawlotsky JM; Pellerin M; Bouvier M; Roudot-Thoraval F; Germanidis G; Bastie A; Darthuy F; Rémiré J; Soussy CJ; Dhumeaux D J Med Virol; 1998 Apr; 54(4):256-64. PubMed ID: 9557291 [TBL] [Abstract][Full Text] [Related]
4. Hepatitis C kinetics: mathematical modeling of viral response to therapy. Layden TJ; Mika B; Wiley TE Semin Liver Dis; 2000; 20(2):173-83. PubMed ID: 10946422 [TBL] [Abstract][Full Text] [Related]
5. Antiviral effect of human recombinant interleukin-12 in patients infected with hepatitis C virus. Lee JH; Teuber G; von Wagner M; Roth WK; Zeuzem S J Med Virol; 2000 Mar; 60(3):264-8. PubMed ID: 10630957 [TBL] [Abstract][Full Text] [Related]
6. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649 [TBL] [Abstract][Full Text] [Related]
7. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta. Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623 [TBL] [Abstract][Full Text] [Related]
8. Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon. Boulestin A; Kamar N; Sandres-Sauné K; Legrand-Abravanel F; Alric L; Vinel JP; Rostaing L; Izopet J J Med Virol; 2006 Mar; 78(3):365-71. PubMed ID: 16419107 [TBL] [Abstract][Full Text] [Related]
9. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia. Shire NJ; Horn PS; Rouster SD; Stanford S; Eyster ME; Sherman KE; Hepatology; 2006 Nov; 44(5):1146-57. PubMed ID: 17058240 [TBL] [Abstract][Full Text] [Related]
11. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Zeuzem S; Schmidt JM; Lee JH; Rüster B; Roth WK Hepatology; 1996 Feb; 23(2):366-71. PubMed ID: 8591865 [TBL] [Abstract][Full Text] [Related]
12. [Relationship between diversity of hepatitis C virus quasispecies and viremia, activity of liver disease and response to interferon therapy]. Tang X; Qian K; Yuan X; Johnson YN Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Jun; 16(2):128-31. PubMed ID: 12196822 [TBL] [Abstract][Full Text] [Related]
13. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715 [TBL] [Abstract][Full Text] [Related]
14. Evolution of hepatitis C virus quasispecies during therapy with IL2 combinated to alpha interferon and ribavirin. Boulestin A; Sandres-Saune K; Alric L; Pipy B; Dubois M; Vinel JP; Izopet J Antivir Ther; 2005; 10(4):499-504. PubMed ID: 16038475 [TBL] [Abstract][Full Text] [Related]
15. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770 [TBL] [Abstract][Full Text] [Related]
16. Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715 [TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081 [TBL] [Abstract][Full Text] [Related]
18. The molecular basis for responsiveness to anti-viral therapy in hepatitis C. Polyak SJ; Gerotto M Forum (Genova); 2000; 10(1):46-58. PubMed ID: 10717257 [TBL] [Abstract][Full Text] [Related]
19. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. Gerotto M; Sullivan DG; Polyak SJ; Chemello L; Cavalletto L; Pontisso P; Alberti A; Gretch DR J Virol; 1999 Sep; 73(9):7241-7. PubMed ID: 10438811 [TBL] [Abstract][Full Text] [Related]
20. The kinetics of hepatitis C virus infection. Zeuzem S Clin Liver Dis; 2001 Nov; 5(4):917-30. PubMed ID: 11685801 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]